A detailed history of Stephens Investment Management Group LLC transactions in Ligand Pharmaceuticals Inc stock. As of the latest transaction made, Stephens Investment Management Group LLC holds 618,696 shares of LGND stock, worth $70.9 Million. This represents 0.88% of its overall portfolio holdings.

Number of Shares
618,696
Previous 652,000 5.11%
Holding current value
$70.9 Million
Previous $54.9 Million 12.81%
% of portfolio
0.88%
Previous 0.79%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 28, 2024

SELL
$82.7 - $110.11 $2.75 Million - $3.67 Million
-33,304 Reduced 5.11%
618,696 $62 Million
Q2 2024

Aug 06, 2024

SELL
$68.53 - $87.91 $3.07 Million - $3.93 Million
-44,758 Reduced 6.42%
652,000 $54.9 Million
Q1 2024

May 14, 2024

BUY
$68.64 - $89.2 $2.56 Million - $3.33 Million
37,324 Added 5.66%
696,758 $50.9 Million
Q4 2023

Feb 13, 2024

BUY
$49.57 - $72.63 $9.51 Million - $13.9 Million
191,870 Added 41.04%
659,434 $47.1 Million
Q3 2023

Nov 14, 2023

BUY
$58.86 - $72.67 $67,924 - $83,861
1,154 Added 0.25%
467,564 $28 Million
Q2 2023

Aug 14, 2023

BUY
$69.53 - $79.33 $787,149 - $898,094
11,321 Added 2.49%
466,410 $33.6 Million
Q1 2023

May 15, 2023

BUY
$65.67 - $77.08 $44,195 - $51,874
673 Added 0.15%
455,089 $33.5 Million
Q4 2022

Jan 26, 2023

BUY
$61.72 - $96.74 $165,286 - $259,069
2,678 Added 0.59%
454,416 $30.7 Million
Q3 2022

Nov 07, 2022

SELL
$0.01 - $107.56 $18 - $197,480
-1,836 Reduced 0.4%
451,738 $38.9 Million
Q2 2022

Aug 03, 2022

BUY
$74.52 - $117.06 $2.68 Million - $4.2 Million
35,904 Added 8.6%
453,574 $40.5 Million
Q1 2022

May 04, 2022

BUY
$94.99 - $151.56 $599,481 - $956,495
6,311 Added 1.53%
417,670 $47 Million
Q4 2021

Feb 15, 2022

BUY
$127.69 - $165.85 $152,589 - $198,190
1,195 Added 0.29%
411,359 $63.5 Million
Q3 2021

Oct 27, 2021

BUY
$102.33 - $144.73 $4.79 Million - $6.77 Million
46,771 Added 12.87%
410,164 $57.1 Million
Q2 2021

Aug 09, 2021

SELL
$113.03 - $155.64 $838,343 - $1.15 Million
-7,417 Reduced 2.0%
363,393 $47.7 Million
Q1 2021

May 14, 2021

SELL
$99.52 - $215.83 $21 Million - $45.6 Million
-211,484 Reduced 36.32%
370,810 $56.5 Million
Q4 2020

Feb 10, 2021

SELL
$80.55 - $106.05 $992,214 - $1.31 Million
-12,318 Reduced 2.07%
582,294 $57.9 Million
Q3 2020

Nov 13, 2020

SELL
$89.56 - $126.72 $2.62 Million - $3.71 Million
-29,303 Reduced 4.7%
594,612 $56.7 Million
Q2 2020

Aug 24, 2020

BUY
$68.28 - $123.65 $3.02 Million - $5.48 Million
44,290 Added 7.64%
623,915 $69.8 Million
Q1 2020

May 14, 2020

BUY
$63.37 - $107.88 $4.53 Million - $7.72 Million
71,525 Added 14.08%
579,625 $42.2 Million
Q4 2019

Feb 14, 2020

SELL
$96.94 - $113.59 $308,269 - $361,216
-3,180 Reduced 0.62%
508,100 $53 Million
Q3 2019

Oct 18, 2019

BUY
$86.25 - $120.16 $5.96 Million - $8.3 Million
69,093 Added 15.63%
511,280 $50.9 Million
Q2 2019

Aug 01, 2019

BUY
$107.38 - $129.34 $1.78 Million - $2.14 Million
16,543 Added 3.89%
442,187 $50.5 Million
Q1 2019

May 03, 2019

BUY
$105.93 - $142.47 $1.83 Million - $2.46 Million
17,299 Added 4.24%
425,644 $53.5 Million
Q4 2018

Feb 11, 2019

BUY
$128.36 - $272.13 $3.33 Million - $7.05 Million
25,912 Added 6.78%
408,345 $55.4 Million
Q3 2018

Nov 14, 2018

SELL
$211.18 - $274.49 $7.06 Million - $9.17 Million
-33,408 Reduced 8.03%
382,433 $105 Million
Q2 2018

Aug 10, 2018

SELL
$150.77 - $207.98 $1.39 Million - $1.92 Million
-9,218 Reduced 2.17%
415,841 $86.5 Million
Q1 2018

May 04, 2018

SELL
$138.63 - $182.62 $648,095 - $853,748
-4,675 Reduced 1.09%
425,059 $70.2 Million
Q4 2017

Feb 05, 2018

SELL
$128.36 - $147.04 $2.76 Million - $3.16 Million
-21,494 Reduced 4.76%
429,734 $58.8 Million
Q3 2017

Nov 08, 2017

BUY
$120.91 - $137.94 $356,684 - $406,923
2,950 Added 0.66%
451,228 $61.4 Million
Q2 2017

Aug 10, 2017

BUY
N/A
448,278
448,278 $54.4 Million

Others Institutions Holding LGND

About LIGAND PHARMACEUTICALS INC


  • Ticker LGND
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 16,882,800
  • Market Cap $1.94B
  • Description
  • Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19;...
More about LGND
Track This Portfolio

Track Stephens Investment Management Group LLC Portfolio

Follow Stephens Investment Management Group LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Stephens Investment Management Group LLC, based on Form 13F filings with the SEC.

News

Stay updated on Stephens Investment Management Group LLC with notifications on news.